The DAPA-CKD trial has shown dapagliflozin, a SGLT2 receptor inhibitor, improves function, and reduces cardiovascular events and mortality. The latter is true regardless being or not diabetic. Patients with chronic kidney failure randomized to dapagliflozin saw improved kidney function, reduced cardiovascular events and increased survival rate. Primary end point, a combination of glomerular filtration deterioration<a href="https://solaci.org/en/2020/09/07/esc-2020-dapagliflozin-in-kidney-failure-the-drug-continues-to-conquer-other-territories/" title="Read more" >...</a>
ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality
Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in patients with heart failure, even in those without diabetes. Adding empagliflozin to optimal medical therapy lowers the risk of cardiovascular events in patients with heart failure and reduced ejection fraction. Such events include heart failure hospitalization, worsening kidney<a href="https://solaci.org/en/2020/09/03/esc-2020-new-sglt2-inhibitor-impacts-heart-failure-mortality/" title="Read more" >...</a>
AHA 2019 | DAPA-HF: Dapagliflozin Effective for all Heart Failure Subgroups
SGLT2 inhibitor dapagliflozin had a consistent impact regardless of glycemic level, age, or general health status. Dapagliflozin was originally developed for the treatment of type 2 diabetes. However, it has had a positive impact on various types of patients with chronic heart failure and reduced ejection fraction, including those without diabetes. This information is derived from<a href="https://solaci.org/en/2019/11/21/aha-2019-dapa-hf-dapagliflozin-effective-for-all-heart-failure-subgroups/" title="Read more" >...</a>
AHA 2018 | PIONEER-HF: Sacubitril/Valsartan in Acute Decompensated Heart Failure
Treating acute decompensated heart failure patients with an angiotensin receptor inhibitor plus a neprilysin receptor inhibitor significantly reduces N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations and clinical events, according to the PIONEER-HF study presented at the American Heart Association (AHA) Congress Scientific Sessions and published simultaneously in the New England Journal of Medicine (NEJM). The study<a href="https://solaci.org/en/2018/11/30/aha-2018-pioneer-hf-sacubitril-valsartan-in-acute-decompensated-heart-failure/" title="Read more" >...</a>
Liver Failure as a Challenge for TAVR
Although surgical risk scores do not include liver failure (LF), patients who suffer from it and undergo cardiovascular surgery present high rates of morbidity and mortality. This is due to alteration of cardiac function, increased infection susceptibility, gastrointestinal complications, and increased bleeding. As regards transcatheter aortic valve replacement (TAVR), these patients have not been included<a href="https://solaci.org/en/2018/05/03/liver-failure-as-a-challenge-for-tavr/" title="Read more" >...</a>
ACC 2018 | Flu Vaccination Reduces Mortality in Heart Failure Hospitalizations
Heart failure patients vaccinated against influenza are at a significantly lower risk of dying, both during flu season and outside of it. Patients with heart failure vaccinated had a 48% lower risk of death during influenza season and a 21% lower risk during the rest of the year. Dr. Fukuta, lead investigator in this study,<a href="https://solaci.org/en/2018/04/09/acc-2018-flu-vaccination-reduces-mortality-in-heart-failure-hospitalizations/" title="Read more" >...</a>
Cardiac Damage: Should we start to assess it?
Courtesy of Dr. Carlos Fava. The current recommendation for aortic valve replacement is based on stenosis severity based on valvular criteria (mean transvalvular gradient, peak aortic velocity and valve index area) and the presence of symptoms, in addition to comorbidities, mainly for risk stratification. However, ventricular damage and/or its effect on cardiovascular hemodynamics are not regarded<a href="https://solaci.org/en/2017/12/20/cardiac-damage-should-we-start-to-assess-it/" title="Read more" >...</a>
TRICS III: Restrictive Transfusion Was Noninferior to Liberal Use in Patients Who Undergo Cardiac Surgery
A large study conducted in 19 countries has found that a policy of restrictive red-cell transfusion during cardiac surgery is just as safe and effective as more liberal policies. TRICS III enrolled 5243 patients and was presented at the American Heart Association (AHA) Scientific Sessions and published simultaneously in the New England Journal of Medicine (NEJM). Patients were<a href="https://solaci.org/en/2017/11/16/trics-iii-restrictive-transfusion-was-noninferior-to-liberal-use-in-patients-who-undergo-cardiac-surgery/" title="Read more" >...</a>
Frequency and Evolution of Cardiac Perforation in Patients with a History of MRS
Courtesy of Dr. Carlos Fava. Coronary perforation (CP) is a very uncommon event (≈0.4%), associated with severe complications that entail risk of death. It has usually been related to patients with a history of myocardial revascularization surgery (MRS). However, this group usually presents lower rates of cardiac tamponade due to pericardial fibrosis caused by surgery. This<a href="https://solaci.org/en/2017/10/05/frequency-and-evolution-of-cardiac-perforation-in-patients-with-a-history-of-mrs/" title="Read more" >...</a>
Success in CTOs caused by restenosis lowers cardiac mortality
Courtesy of Dr. Carlos Fava. Nowadays, chronic total occlusions (CTO) due to in-stent restenosis (ISR) represent 5%-25% of all coronary angioplasties. These lesions pose a new and true challenge, since CTOs are often associated with stent-related problems (fractures, lack of expansion, overlapping, deformation), extreme tortuosity, severe calcification, tandem lesions after CTO, and aorto-ostial lesions, with little<a href="https://solaci.org/en/2017/06/26/success-in-ctos-caused-by-restenosis-lowers-cardiac-mortality/" title="Read more" >...</a>